For research use only. Not for therapeutic Use.
L-Alanosine（Cat No.:R009331）is an amino acid analogue and a potent inhibitor of AMP deaminase, an enzyme involved in purine metabolism. It has demonstrated antitumor activity by disrupting purine biosynthesis, leading to the depletion of nucleotides essential for DNA and RNA synthesis. L-Alanosine’s ability to inhibit cell proliferation makes it a candidate for cancer therapy, especially in purine-dependent cancers. Its selectivity for inhibiting tumor cells while sparing normal cells offers promising therapeutic potential. L-Alanosine’s pharmacological profile highlights its potential use in targeted cancer treatments and metabolic research.
| Catalog Number | R009331 |
| CAS Number | 5854-93-3 |
| Synonyms | 3-(Hydroxynitrosoamino)-L-alanine; L-2-Amino-3-(N-nitroso)hydroxylaminopropionic Acid; Alanosine; NSC 153353; NSC 529469; SDX 102; |
| Molecular Formula | C3H7N3O4 |
| Purity | ≥95% |
| Target | Antibiotic |
| Storage | -20°C |
| IUPAC Name | (Z)-[(2S)-2-amino-2-carboxyethyl]-hydroxyimino-oxidoazanium |
| InChI | InChI=1S/C3H7N3O4/c4-2(3(7)8)1-6(10)5-9/h2,9H,1,4H2,(H,7,8)/b6-5-/t2-/m0/s1 |
| InChIKey | ZGNLFUXWZJGETL-YUSKDDKASA-N |
| SMILES | C([C@@H](C(=O)O)N)/[N+](=N/O)/[O-] |
| Reference | </br>1:A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Kindler HL, Burris HA 3rd, Sandler AB, Oliff IA.Invest New Drugs. 2009 Feb;27(1):75-81. doi: 10.1007/s10637-008-9160-1. Epub 2008 Jul 11. PMID: 18618081 </br>2:Circadian pharmacology of L-alanosine (SDX-102) in mice. Li XM, Kanekal S, Crépin D, Guettier C, Carrière J, Elliott G, Lévi F.Mol Cancer Ther. 2006 Feb;5(2):337-46. PMID: 16505107 Free Article</br>3:T-state active site of aspartate transcarbamylase: crystal structure of the carbamyl phosphate and L-alanosine ligated enzyme. Huang J, Lipscomb WN.Biochemistry. 2006 Jan 17;45(2):346-52. PMID: 16401065 </br>4:EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine. Batova A, Cottam H, Yu J, Diccianni MB, Carrera CJ, Yu AL.Blood. 2006 Feb 1;107(3):898-903. Epub 2005 Oct 18. PMID: 16234352 Free PMC Article</br>5:Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells. Li W, Su D, Mizobuchi H, Martin DS, Gu B, Gorlick R, Cole P, Bertino JR.Oncol Res. 2004;14(7-8):373-9. PMID: 15301428 </br>6:Determination of derivatized l-alanosine in plasma by liquid chromatography-tandem mass spectrometry. Gantverg A, Elliott G, Pineault J, Demers R.J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Apr 25;803(2):311-5. PMID: 15063341 </br>7:Identification of gene expression profiles predicting tumor cell response to L-alanosine. Efferth T, Gebhart E, Ross DD, Sauerbrey A.Biochem Pharmacol. 2003 Aug 15;66(4):613-21. PMID: 12906926 </br>8:Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study. Von Hoff DD, Green SJ, Neidhart JA, Fabian C, Budd T, Boyd JF, Osborne CK.Invest New Drugs. 1991 Feb;9(1):87-8. No abstract available. PMID: 2026487 </br>9:Increased tumor control rates in murine fibrosarcoma by combined therapy with L-alanosine and radiation. Hong SS, Alfieri AA, Kim SH, Kim JH.Jpn J Cancer Res. 1989 Jun;80(6):592-6. PMID: 2503478 </br>10:Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma. Elson PJ, Kvols LK, Vogl SE, Glover DJ, Hahn RG, Trump DL, Carbone PP, Earle JD, Davis TE.Invest New Drugs. 1988 Jun;6(2):97-103. PMID: 3170135 |
